BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 28655592)

  • 1. Prognostic Value of Radiation Pneumonitis After Stereotactic Body Radiotherapy: Effect of Pulmonary Emphysema Quantitated Using CT Images.
    Yamamoto T; Kadoya N; Sato Y; Matsushita H; Umezawa R; Kubozono M; Ishikawa Y; Kozumi M; Takahashi N; Morishita Y; Katagiri Y; Sato K; Ito K; Takeda K; Jingu K
    Clin Lung Cancer; 2018 Jan; 19(1):e85-e90. PubMed ID: 28655592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emphysema quantification on computed tomography and its value in predicting radiation pneumonitis in lung cancer treated by stereotactic body radiotherapy.
    Ye L; Zhang Y; Li T; Zhang X; Shi S; Zhao Q; Zeng Z; He J
    J Radiat Res; 2019 May; 60(3):371-379. PubMed ID: 30968939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic analysis of radiation pneumonitis: carbon-ion radiotherapy in patients with locally advanced lung cancer.
    Hayashi K; Yamamoto N; Karube M; Nakajima M; Matsufuji N; Tsuji H; Ogawa K; Kamada T
    Radiat Oncol; 2017 May; 12(1):91. PubMed ID: 28558766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosimetric factors predicting radiation pneumonitis after CyberKnife stereotactic body radiotherapy for peripheral lung cancer.
    Nakamura M; Nishimura H; Nakayama M; Mayahara H; Uezono H; Harada A; Hashimoto N; Ejima Y; Ishihara T; Sasaki R
    Br J Radiol; 2016 Dec; 89(1068):20160560. PubMed ID: 27805837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients with severe emphysema have a low risk of radiation pneumonitis following stereotactic body radiotherapy.
    Ishijima M; Nakayama H; Itonaga T; Tajima Y; Shiraishi S; Okubo M; Mikami R; Tokuuye K
    Br J Radiol; 2015 Feb; 88(1046):20140596. PubMed ID: 25490255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and dosimetric predictors of radiation pneumonitis in early-stage lung cancer treated with Stereotactic Ablative radiotherapy (SABR) - An analysis of UK's largest cohort of lung SABR patients.
    Saha A; Beasley M; Hatton N; Dickinson P; Franks K; Clarke K; Jain P; Teo M; Murray P; Lilley J
    Radiother Oncol; 2021 Mar; 156():153-159. PubMed ID: 33333139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of dosimetric factors with the development of symptomatic radiation pneumonitis in stereotactic body radiotherapy.
    Ryckman JM; Baine M; Carmicheal J; Osayande F; Sleightholm R; Samson K; Zheng D; Zhen W; Lin C; Zhang C
    Radiat Oncol; 2020 Feb; 15(1):33. PubMed ID: 32054487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The risk and predictors for severe radiation pneumonitis in lung cancer patients treated with thoracic reirradiation.
    Ren C; Ji T; Liu T; Dang J; Li G
    Radiat Oncol; 2018 Apr; 13(1):69. PubMed ID: 29661254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy.
    Barriger RB; Forquer JA; Brabham JG; Andolino DL; Shapiro RH; Henderson MA; Johnstone PA; Fakiris AJ
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):457-62. PubMed ID: 21035956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting risk factors for radiation pneumonitis after stereotactic body radiation therapy for primary or metastatic lung tumours.
    Okubo M; Itonaga T; Saito T; Shiraishi S; Mikami R; Nakayama H; Sakurada A; Sugahara S; Koizumi K; Tokuuye K
    Br J Radiol; 2017 May; 90(1073):20160508. PubMed ID: 28195507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutrophil-lymphocyte ratio and a dosimetric factor for predicting symptomatic radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent chemoradiotherapy.
    Lee YH; Choi HS; Jeong H; Kang KM; Song JH; Lee WS; Lee GW; Song HN; Kim HG; Kang MH; Rhee DY; Jeong BK
    Clin Respir J; 2018 Mar; 12(3):1264-1273. PubMed ID: 28618180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival in Patients Treated With Lung Stereotactic Body Radiation Therapy (SBRT).
    Glick D; Lyen S; Kandel S; Shapera S; Le LW; Lindsay P; Wong O; Bezjak A; Brade A; Cho BCJ; Hope A; Sun A; Giuliani M
    Clin Lung Cancer; 2018 Mar; 19(2):e219-e226. PubMed ID: 29066051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose--volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer.
    Matsuo Y; Shibuya K; Nakamura M; Narabayashi M; Sakanaka K; Ueki N; Miyagi K; Norihisa Y; Mizowaki T; Nagata Y; Hiraoka M
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e545-9. PubMed ID: 22436782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is severe emphysema, as defined by quantitative CT measurement, a negative risk factor of radiation fibrosis?
    Saito T; Nakayama H; Yamada T; Shiraishi S; Tokuuye K
    Br J Radiol; 2018 Jul; 91(1087):20170921. PubMed ID: 29651875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe COPD is correlated with mild radiation pneumonitis following stereotactic body radiotherapy.
    Takeda A; Kunieda E; Ohashi T; Aoki Y; Oku Y; Enomoto T; Nomura K; Sugiura M
    Chest; 2012 Apr; 141(4):858-866. PubMed ID: 21885726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin-converting enzyme inhibitors decrease the risk of radiation pneumonitis after stereotactic body radiation therapy.
    Harder EM; Park HS; Nath SK; Mancini BR; Decker RH
    Pract Radiat Oncol; 2015; 5(6):e643-9. PubMed ID: 26412341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of clinical, tumour-related and dosimetric factors in grade 0-1, grade 2 and grade 3 radiation pneumonitis after stereotactic body radiotherapy for lung tumours.
    Takeda A; Ohashi T; Kunieda E; Sanuki N; Enomoto T; Takeda T; Oku Y; Shigematsu N
    Br J Radiol; 2012 May; 85(1013):636-42. PubMed ID: 22253343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early graphical appearance of radiation pneumonitis correlates with the severity of radiation pneumonitis after stereotactic body radiotherapy (SBRT) in patients with lung tumors.
    Takeda A; Ohashi T; Kunieda E; Enomoto T; Sanuki N; Takeda T; Shigematsu N
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):685-90. PubMed ID: 20510193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study.
    Feddock J; Arnold SM; Shelton BJ; Sinha P; Conrad G; Chen L; Rinehart J; McGarry RC
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1325-31. PubMed ID: 23265574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: the potential risk of extensive radiation pneumonitis.
    Yamaguchi S; Ohguri T; Ide S; Aoki T; Imada H; Yahara K; Narisada H; Korogi Y
    Lung Cancer; 2013 Nov; 82(2):260-5. PubMed ID: 24054547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.